New Blood Test Identifies Neuroendocrine Subtype of Advanced Prostate Cancer

Roughly 10-15% of individuals with metastatic castration-resistant prostate cancer (CRPC) eventually develop neuroendocrine prostate cancer (NEPC), a challenging cancer subtype. This transformation is marked by a change from androgen-dependent cancer cells to those that no longer respond to androgens. Diagnosing NEPC typically involves a biopsy from a metastatic tumor, but this can be uncertain due to timing issues and the heterogeneous nature of metastatic tumors. Now, researchers have developed a blood test that can reliably detect NEPC and differentiate it from CRPC-adenocarcinoma (CRPC-adeno).

In previous research, an international team of researchers from Dana-Farber Cancer Institute (Boston, MA, USA and the University of Trento (Trento, Italy) examined biopsy tissue samples to identify genetic and epigenetic shifts accompanying this shift from cancer cells that are dependent on hormones called androgens to cancer cells that no longer even recognize androgens. They discovered distinctive genome-wide epigenetic alterations, particularly in DNA methylation, that differentiate CRPC-adeno from NEPC. These changes can be identified in blood, as the body naturally releases cell fragments, including cell-free DNA (cfDNA), which carry these epigenetic markers. This insight led to the development of the NEMO (NEuroendocrine MOnitoring panel) blood test. NEMO examines cfDNA in blood plasma for specific DNA fragments and assesses their methylation levels. It reports two critical metrics: the tumor fraction (the ratio of tumor to normal DNA in the blood, indicating disease burden) and the tumor type (CRPC-adeno or NEPC), presented as a score on a spectrum to account for possible mixed cancer types.

NEMO was tested in various preclinical prostate cancer models and blood samples from patients with known prostate cancer subtypes, demonstrating high accuracy in subtype identification. In two clinical trials involving aggressive CRPC patients, NEMO’s tumor fraction estimates aligned with established disease burden measures, suggesting its potential in tracking treatment response, particularly valuable as standard measures like prostate-specific antigen levels become less reliable during the transition to NEPC. The test accurately identified NEPC patients and also pinpointed individuals showing early signs of transitioning to NEPC. The insights provided by the NEMO panel could guide clinicians in choosing targeted treatments and assist researchers in understanding the disease more deeply. Additionally, this testing method holds promise for application in other cancer types to differentiate between subtypes.

"As prostate cancer treatments get more effective, we expect the emergence of different types of treatment resistance like neuroendocrine prostate cancer that help them evade treatment," said Himisha Beltran, associate professor of medicine at Dana-Farber Cancer Institute. "We hope this blood test can be used by clinicians to determine if a patient is developing neuroendocrine prostate cancer."

Related Links:
Dana-Farber Cancer Institute
University of Trento

Visit expo >

New

Gold Member

Clinical Drug Testing Panel

DOA Urine MultiPlex

POC Helicobacter Pylori Test Kit
Hepy Urease Test

Automatic Hematology Analyzer

DH-800 Series

Urine Chemistry Control

Dropper Urine Chemistry Control